XML 40 R27.htm IDEA: XBRL DOCUMENT v3.24.3
REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)
 9 Months Ended
Sep. 30, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of Changes in Contract Assets and Contract Liabilities
The following table summarizes the changes in the contract asset and liability balances for the nine months ended September 30, 2024:
Dollars in thousandsTotal
Contract Asset
Contract asset, January 1, 2024
$9,233 
Transferred to trade receivable from contract asset included in beginning of the year contract asset$(9,233)
Contract asset, net of transferred to trade receivables on contracts during the period$7,828 
Contract asset, September 30, 2024
$7,828 
Contract Liability
Contract liability, January 1, 2024
$16,252 
Recognition of revenue included in beginning of year contract liability$(6,616)
Contract liability, acquired with Acclarent$3,984 
Contract liability, net of revenue recognized on contracts during the period$4,447 
Foreign currency translation$21 
Contract liability, September 30, 2024
$18,088 
Schedule of Disaggregation of Revenue
The following table presents revenues disaggregated by the major sources of revenues for the three and nine months ended September 30, 2024 and 2023 (dollar amounts in thousands):
Three Months Ended September 30, 2024Three Months Ended September 30, 2023Nine Months Ended September 30, 2024Nine Months Ended September 30, 2023
Neurosurgery$175,956 $209,229 $583,726 $607,902 
Instruments54,238 49,920 153,148 152,523 
ENT(1)
40,588 9,056 92,103 26,946 
Total Codman Specialty Surgical270,782 268,205 828,977 787,371 
Wound Reconstruction and Care80,460 88,071 249,032 280,129 
Private Label29,592 26,145 89,872 77,034 
Total Tissue Technologies110,052 114,216 338,904 357,163 
Total revenue$380,834 $382,421 $1,167,881 $1,144,534 
(1) Prior period revenues included within our instruments business have been reclassified under the ENT business.